More Related Content Similar to Amazing Facts and Figures - A compilation by Aagami (20) More from Aagami, Inc. (20) Amazing Facts and Figures - A compilation by Aagami1. INDIA
Amazing Facts and Figures
Dinesh Jain, Founder CEO
Connecting Global to India | Realizing Possibilities
Page 1
2. “India is no longer seen as a America's back office. India has moved up the value chain as a America's knowledge
partner. We need help from the Indian companies in job creation. If Indian firms can create jobs for the hinterland of
America, it will dispel anti - sourcing rhetoric.”
- Ron Somers, President,
US India Business Council | January 2011
“This coming year, I believe Indian participation at Davos can highlights the country's thought leadership. At time
when the world is searching for a new model of economic development, India's experience as a crucible for new
types of inclusive growth gives its a special role among developing countries.”
- Klaus Schwab, Founder & Chairman,
World Economic Forum | February 2010
“India is the cradle of the human race, the birthplace of human speech, the mother of history, the
grandmother of legend, and the great grand mother of tradition. Our most valuable and most constructive
materials in the history of man are treasured up in India only”
- Mark Twain, American Author 1835- 1910
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 2
3. Overview of Contents
India – an Introduction
India LifeSciences Industry Snapshot
Major Centers of Lifesciences in India – Public & Private
Major International Deals with India by Global Companies
What Indian LifeSciences firms are Looking for
About Aagami and how it supports global companies in their India Initiatives
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 3
4. India – A Brief Introduction India
- Population of continent Africa- 1 Billion
(second most populous Continent)**
- 15% of the world's human population
Africa
India compares in
population with these - Nation of 1.21 Billion population*
continents although it is a - 17.5% of world human population
single country. - 28 states & 7 union territories
Europe
Union
- Population of Continental Europe –
739 Million -~ 10% of the world's human
population
Source: Africa Population- Explore DIA, Africa Population 2013, Europe Union Population- 502.5mn Euro stat News Release-July 2011; The EU in the
world – population - EU contributes in world population http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/The_EU_in_the_world_-
_population; India -India Online pages- Population for 2011, India contributing to world population : India today. in
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 4
5. India – A Brief Introduction
A Treasure of Languages in India One of the Oldest Civilizations
• There are 22 official languages in India. While • India civilization is one of the oldest civilizations
The number of languages spoken in India, as per of the world even older than Egypt and
The Economist are 438 with English most widely Mesopotamia.
spoken and used in interstate communications.
– Economist also has a Greenberg diversity index which
• Indian civilization is 8000 year old.
measures the probability of two random citizens – Latest research has put the date of the origin of the
sharing the same mother tongue. An index of 1 being Indus Valley Civilisation at 6,000 years before Christ,
no two people picked at random would be speaking which contests the current theory that the settlements
the same language, India’s Greenberg diversity around the Indus began around 3750 BC
stands at 0.94. – India invented the Number System. Zero was invented
– On sheer number of languages spoken, India stands by Arybhatta.
fourth behind Papua New Guinea (830), Indonesia – The place value system, the decimal system was
(719) and Nigeria (514). On the diversity index, India developed in India in 100 BC.
(0.94) stands third behind Papua New – The Algebra, Trigonometry & Calculus came from India
Guinea(0.99) and Congo (0.95).
– The world university was established in Takshila in 700
• English is widely spoken in India. The BC
subcontinent ranks third in the world, after the – Even today some ancient traditions are still practiced
USA and UK in terms of English speakers • Though so old in existence, India is a nation,
• In education, English is the most common which is considered to be youngest in its
medium (87% of all the situations). demographics. We have about 550 million
– English is the language of the legal system, higher youth in the nation.
education, pan-regional administrative network, – With more than 50 percent of the population below 30
science and technology, trade and commerce years of age, India today has an advantage of the
demographic dividend.
• India is the largest democracy in the world
Source: Languages in India, Vol 3- 5 May 2003, Indus Valley 2,000 years older than thought- Hindustan Times -November 04, 2012, Silver Evolution-
http://silverevolution.wordpress.com/2011/12/07/india-youngest-nation-today-silver-tomorrow/
http://eci.nic.in/eci_main1/eci_news/AddressbyDrAPJAbdulKalam.pdf
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 5
6. Economic Indicators of India – Fast growing and Stable
• India demonstrates faster and stable growth than
most other countries in the Dow Jones list of
2000 INDIA GDP 1847.98
emerging economies
Billions of US Dollars 1729.01
1800
1600 • Indian economy ranks 3rd largest in the world in
1380.64
1400 PPP (Purchase Power Parity)
1242.43 1213.78
1200
951.34 • India is expected to become the second largest
1000 economy in the long run.
810.15
800 700.92
599.46
600 507.19 • Among emerging markets, India is next only to
China with respect to share in world GDP
400
200
• Among emerging markets India has one of the
0 most favourable tax regimes, a very crucial factor
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 for business growth
– On the scale of most favourable tax rate score
where 10 was least tax (10= least tax), India score
Years was 8
Source: www.tradingeconomics.com| | The World Bank Group
• India contributes total 6% in world GDP (PPP) 2011 • As per the Nielsen Global Consumer Confidence
• The country’s GDP has been growing at an average rate of Index (various reports), Consumer confidence
8.6% for last five years has been consistently above the world average
Source: India The Incredible Investment Destination , Fact Book- Dept. Of Economic Affairs, Ministry of Finance, GOI, June 2012, IMF World
Economic Outlook (April 2012)
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 6
7. India’s Robust Macroeconomic Performance
Key Parameters 2005-06 2011-12 Change
Real GDP (INR Billions) 32, 542 52, 220 60 % higher
Real Per capita GDP (INR) 33, 548 46, 221 38% higher
Investment/ GDP (%) 35.8 37.6 5% higher
Exports (US $ bn) 103 303 194% higher
General Government Gross Debt (% GDP) 77.4 64.9** 16% lower
Workers Remittance (US$ bn) 28.0+ 63.7++ 127%
Gross International Reserves (US $ bn) 151# 294## 94% higher
Foreign Direct Investment inflow (US $ bn) 9.1 46.8 414% higher
Foreign Direct Investment outflow (US$ bn) 6.1 25.8** 323% higher
Source: Reserve Bank of India data (as on March 2012, IMF WEO Database April 2012, ** FY 2010- 11, + for calendar year 2006, ++ for
calendar year 2011, , # as on 31 March 2006, ## As on March 2012; Department of Economic Affairs, GOI
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 7
8. India’s Key Strengths include....
Stable financial systems, healthy sectoral diversity of economy, highly educated workforce and
openness in Trade
• Good growth prospects supported by ongoing economic
India outperforms other fast growing economies liberalisation and strong domestic demand
in terms of change in openness
• Stable financial system, Strong external liquidity position
• High degree of political stability in comparison to many countries
India 170
• Vibrant, transparent and high-yielding capital markets
• High savings and investment ratios
Russia 97 • Strong and competitive private sector
B Brazil • Low susceptibility to event risk
E S.Africa • Steadily rising government revenues
Mexico 74
T
China
T
China 74 E Mexico • Healthy sectoral diversity of economy
R Russia • Largely local currency denominated debt
S.Africa
• Conducive investment climate
40 India
• Strong financial regulatory framework
• High growth in exports
Brazil 40 • Strong demographic advantage
• Highly educated work force
0 50 100 150 200
• Innovative society
India’s economy has strong fundamentals & is host to
The country ranks higher than many countries in key several eminent global corporate giants that are leaders
parameters such as market size (4th) & innovation in their respective fields. According to the Global
(39th) . India has also a good financial market (17th) Competitiveness Report 2010-11, India ranks at 51
among 139 countries
Source: Department of Economic Affairs, Government of India, Doing Business in India- E&Y report , 2011, World Bank GDI Database
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 8
9. India : Increasing foreign assets
Foreign Reserves have grown from 54.1 USD mn in 2001-02 and peaked to 309.7 USD mn in 2007-08. India
is hotspot for FDI, much ahead than US and UK as per FDI Confidence Index 2012
High Foreign Reserves India is an attractive destination for FDI
2011-12 294 1.9
2001-02 2
1.7 China
2010-11 304.8 1.8 1.6
2002-03 1.5 1.5 1.5 1.5 1.5
2009-10 279 1.6 1.4 1.4 India
2003-04 1.4
2008-09 251.9 Brazil
2004-05 1.2
2007-08 309.7 US
1
2006-07 199.1 2005-06
0.8 Germany
2005-06 151.6 2006-07 0.6 Australia
2004-05 141.5 2007-08 0.4
2003-04 112.9 0.2 Singapore
2008-09
2002-03 76.1 0 UK
2009-10
2001-02 54.1 Malaysia
2010-11
0 100 200 300 400 South Africa
>> India’s net foreign assets are higher than most other
Emerging Market Economy (EMEs)*
FDI Confidence Index 2012 – India ranked 2nd
in the world, an improvement from its 3 rd rank in 2010
>> India’s sovereign net foreign assets is 10.5 % of GDP in
EMEs *
Source: Department of Economic Affairs, Government of India; * - Fitch Ratings, March 2012; Reserve Bank of India
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 9
10. Lifesciences is a regulated and fast growing industry in
India – (1 of 2)
Life Science Market - $ 21 billion.
Experiencing rapid growth, The Indian healthcare sector is
projected to have a CAGR of expected to reach US$ 100 billion
Indian healthcare is $65 billion
around 25-30% between FY2011 by 2015, $280 billion by 2020.
(December 2012)
& FY2013* . India accounted for Growing 20 per cent year-on-year
19 per cent of the total revenues (y-o-y), as per rating agency Fitch
in Asia Pacific#
India Pharma market is expected
India is the 3rd
largest Pharma to touch US$ 74 billion in Sales The outlook on the Indian
market by volume and 13th in by 2020 from the current US$ 11 pharmaceutical industry remains
terms of value globally. By 2015, it Billion, according to a favourable, according to a report
will rank 10th in world** PricewaterhouseCoopers (PwC) by ICRA and Moody's
report.
Domestic formulation market India's exports of drugs, The size of the Indian
stood at Rs 58,300 crores (US$ pharmaceutical and fine formulations market, which
10.54 billion) and has been chemicals grew by 27 per cent to currently stands at around Rs
ranked third in terms of volume Rs 60,000 crores (US$ 10.85 62,000 crores (US$ 11.21 billion),
and tenth in terms of value, billion) for the year ended March is growing at 15-20 per cent
globally. 2012*** annually.
Source: *Aspiring Mind-http://www.aspiringminds.in/industries/life-sciences.html; ** India Pharma 2015- Unlocking the potential of Indian
Pharmaceuticals market -> McKinsey & Co; ***Pharmaceutical Exports Council of India (Pharmexil).; IBEF, #- Seven Indian companies among
Asia's top 20 life science firms- Deccan Herald , July 6, 2012 Inc. 2013 | All rights reserved | www.aagami.net
© Aagami, Page 10
11. Lifesciences is a regulated and fast growing industry in
India (2 of 2) Top 10 supplier countries 2011 for UNICEF
India boast of over 20,000 pharmaceuticals and biotech Based on country of invoice, in $ millions
companies. 60,000 distributors and 700,000 to 800,000
pharmaceuticals retailers.* Supplier Country Amount
More than top 20 companies have presence in the regulated India $ 467.00
market (US, Canada, Western EU and Japan) Switzerland $ 299.00
More than 100 companies from India are present in 50+ Belgium $ 239.00
countries.
USA $ 183.00
India is known as “Pharmacy of Developing world”. Globally
successful in ‘Generics’
France $ 163.00
67% of medicines exports from India go to developing Denmark $ 128.00
countries. Italy $ 54.00
Approx. 50% of the essential medicines that UNICEF United Kingdom $ 37.00
distributes in developing countries come from India Pakistan $ 32.00
75-80% of all medicines distributed by the International
Source: UNICEF – Supply Annual Report 2011
Dispensary Association (IDA) to developing countries are
http://www.unicef.org/supply/files/UNICEF_Supply_Annual_Report
manufactured in India. (IDA is a medical supplier operating _2011_web.pdf
on a not-for-profit basis for distribution of essential
medicines to developing countries.)
If vaccines are excluded, India is the source of approx. 50% of the essential medicines
UNICEF distributes in developing countries
Source:* -The Right Spice. Pharmaceutical Market Entry in India – Deloitte; http://www.doctorswithoutborders.org/news/access/background_paper_indian_generics.pdf
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 11
12. Indian pharmaceutical industry Today
Top 10 Destinations of Indian pharma
products Apr-Dec 2010
Huge Export Happening Sr.No Countries Exported
To
Amount (US$
millions)
India’s largest export destination for Pharma products is still 1 USA 1791.0
the USA, followed by the UK, Germany, South Africa and
Russia. 2 UK 263.9
3 Germany 243.6
More than 50 per cent share of exports is by way of dosage
4 South Africa 222.6
forms.
5 Russia 221.4
India currently exports drug intermediates, Active
6 Brazil 165.0
Pharmaceutical Ingredients (APIs), Finished Dosage
Formulations (FDFs), Bio-Pharmaceuticals and Clinical 7 Nigeria 154.1
Services to various parts of the world.
8 Kenya 137.3
India had more than 175 US- FDA approved manufacturing 9 Netherlands 131. 7
facility, which makes it the only country outside the US to
have highest FDA certified manufacturing facilities (2009) 10 Turkey 119.0
Source: Doing Business in India- E&Y 2011; Growth of Indian Pharmaceutical Source: Directorate General of Commercial Intelligence and
Industry: Impact of Indian, US and European Patent Laws and Regulatory Statistics (DGCIS) Kolkata
Requirements, July 2012
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 12
13. Indian companies to benefit from the ongoing wave of
patent expiries
Details of ANDA filings by Leading Indian companies
100% 7
90% 14
54 38
80% 152 63
77 65 26
70% 10 38 Para IV
60%
Pending (Non Para IV)
50%
Approved
40% 23
133
30% 225 135 103 69
65
20%
48 DMFs Filing by Indian and Chinese Pharmaceutical
10%
Companies (USFDA statistic)
0%
Riding on back of the generic opportunity, Indian companies
have capitalized on the growth prospects to emerge as
formidable players in the US generics markets.
Most of the leading players have significantly expanded their
Source: Company Reports; ICRA Estimates; Sun Pharma- Includes ANDA filings in line with the patent expiration cycle.
filing from Taro. Details of Para IV opportunities of Sun Pharma &
Cadila are not available. The quality of the filings by top Indian companies has also
significantly improved over the years with complex molecules,
INDIAN PHARMACEUTICAL SECTOR Growth drivers strengthen in non-standard categories (i.e. inhalers, injectables, oral
the near term; Patent expiries in the U.S. & Europe and domestic contraceptive, ophthalmic etc.) and Para IV/FTFs forming
market are key industry Update ; March 2012 increasing share of their pipeline
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 13
14. India Biotechnology & Bio-pharma Sector has witnessed
continuous and steady growth
Biotech industry crossed revenue of $4161 billion in FY CRAMS sector in India valued at $8.2 Billion with 41.4%
2011- 2012. growth trajectory, Set To Triplicate global average of
12.6%
Biotech registers a CAGR of 11.75% during 2008-12 an CAGR Market for Contract Research Organization in India to
of 24% during last 10 yrs. double to USD 1 Billion by 2016
•The local $485 million clinical research market is growing at a 11-13%
Biopharma dominates the India’s Biotech Industry with he as the country gains increasing favour as a base for global clinical trials
(phase I-IV)
revenue share of 61.6%.
“India's diagnostic market grows at 20%”
Abundant speciality health institutions
- BioSpectrum Asia , August 2012
•India has 16000+ hospitals
•The speciality hospitals in India have all facilities to cater medical tourism. •The diagnostics market in India is witnessing a 20 percent growth
which is the faster than any country in the world (the growth in the US
•India’s medical tourism business is predicted to generate USD 2.4 billion a
is one-to-two percent
year by 2012 and is growing at 30 per cent a year.
•The diagnostics market revenue in 2011-12 touched $600 million as
•Vast range of medical treatments from simple dental procedures to
against $510 million in 2010-11
complex cardiac surgeries is being offered by India.
•Those patients undergoing treatment in India can save 60%-95% of their
treatment cost.
Source: BioSpectrum Asia; http://northbridgeasia.com/ResearchReports/Northbridge%20Capital_India%20Hospitals%20Reseach_March%202011.pdf
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 14
15. India’s Paradigm shift towards Innovation
Paradigm has shifted from manufacturing quality generics to innovation and novel. India
significantly contributes to the growth of the emerging “ hybrid “model
Source: A Ringside view of the Pharma Industry, Ranjit Shahani – Country President, Novartis India presentation at ValuexIndia, Mumbai, November 2011
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 15
16. Global Pharma companies keen to address opportunities offered
by fast growing Indian market......
On account of the growth slowdown in Developed countries
Other Deals for R&D Type of Alliances
Indian company Pharma MNCs Products
Glenmark (2004) Forest Asthma & anti
Laboratories Lung infection
Piramal Research Merck (further Cancer
(2007) extension in deal
for 2012)
Glenmark (2007) Eli Lilly Pain relief
Serum Institute of MSD Pneumococcal
India (2011) conjugate vaccine
The country’s growing
capabilities in contract manufacturing, Bristol Myers Squibb (BMS ) uses a slew of alliances, partnerships and
R&D and clinical trials also make it a acquisitions to complement its internal capabilities in drug discovery and
preferred outsourcing partner for global development.
Pharma at every stage of the value chain.
BMS calls its string of pearls strategy in which each transaction will be
aligned to the company’s focus on specific disease areas.40% of BMS
patents and 50% of revenue come from such alliances.
Source: India Pharma Inc. Enhancing value through alliances and
Partnerships – Pharma Summit- 2011(PwC & CII Report)
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 16
17. Opportunities for Global companies in India
Ride on India’s
Low production, R&D strength to tap the
and clinical trial cost $150 billion generic
market
As treatment costs are
Biotechnology
significantly lower with
expected to be $8
no waiting period,
Billion by 2015
medical tourism is set
Huge domestic market,
despite price controls, To grow more than
an opportunity— 25% over the next five
insurance and rural years
healthcare
Source: http://www.ipapharma.org/pt/July2012/45-49.pdf
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 17
18. Benefits to Global companies by Collaboration with Indian
Companies Pharma MNCs collaborating with Indian companies
Enhancing value through alliances and Partnerships bring to table new products, latest technology,
higher investments, quality systems and the
knowledge of regulatory process
On their part, Indian companies provide local
market knowledge, cost advantage and local
scientific talents.
Such alliances have the potential to bring
significant benefits to both parties and value to
society as a whole. Such partnership bring in new
drugs and therapies to the market and increase
patient's awareness about diseases and wider
treatment choices available
>> Lilly is currently transforming itself from a traditional fully
integrated pharmaceutical company into a fully integrated
pharmaceutical network, so that it can draw on a range of
resources beyond its own walls.
>> Lilly hopes teaming up with the other organization to create
virtual R&D programmes will enable it to get better access
innovation, reduce costs, manage risks more efficiently and
enhance productivity. For example, the Chorus project is a virtual
organization to take molecules quickly to proof of concept.
>> Lilly also uses external networks comprising third parties such
as Piramal Life Science, Hutchinson MediPharma, and Suven
Source: India Pharma Inc. Enhancing value through alliances and Life Science in the development of molecules
Partnerships – Pharma Summit- 2011(PwC & CII Report)
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 18
19. India’s large pool of scientific manpower and cost advantage
will see boom in collaborations
The pharmaceutical industries in the US and Europe are facing
severe financial constraints which are expected to worsen in the Relative Comparison - Cost advantage in India(%)
years ahead.
The Pharma companies are under increasing pressure to reduce Parameters Total cost in %
expenditure due to, the increasing cost of introducing New Cost in Developed 100%
Molecular Entities (NMEs) (more than $3 billion in 2008),
tightening FDA regulatory issues, blockbuster drugs worth more
countries
than $100 billion set to expire by 2014 and drying pipelines Production cost in India 50%
These pressures are expected to drive the companies towards low-
cost countries such as India to perform their R&D activities, one of R& D cost in India 12.5%
their major expenses.
Clinical trial cost in India 10%
With increasing pressures on curbing healthcare costs in the US,
India’s low-cost manufacturing capabilities coupled with attention Such deals have helped Indian base to gain the
to quality (India has the highest number of FDA-approved title of a genuine intellectual contributor
manufacturing plants outside the US) will be sought by MNCs
India has a large pool of scientific manpower which can be used in Several pharmaceuticals giant firms like Lilly &
drug discovery, development and clinical trials BMS have already begun to use more collaborative
India's diverse genetic pool of treatment-naive population is Models
attractive for clinical trials
The increasing numbers of co-development and alliances taking
Thus, India has emerged as the promising
place between Indian and Pharma companies speaks out in itself
about the conducive environment and policies , protection and country in Drug discovery and more patent
confidentiality of IP filing will be witnessed in years to come
Source: Drug discovery trends in India and China, Express Pharma- June 2010, Pharmaceuticals Export Promotion council (Pharmexil) ; India
Pharma Inc. Enhancing value through alliances and Partnerships – Pharma Summit- 2011(PwC & CII Report
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 19
20. The year 2012 showed some big investment and joint
collaboration taking place in India (1/3)
• Elder Pharma Forms JV With Russian Firm - Holding PharmaEco
• India's Transasia Bio-Medical acquires US based companies - Drew Scientific and JAS Diagnostics
December • Sun Pharma acquires Generic unit - URL Pharma from Takeda of Japan
• Indian Pharma exports grew over 23% in 2011-12: Pharmexcil
2012 • India's Claris forms a JV with Japan's Otsuka for Injectables and Nutrition business in a INRs. 1313
Crores transaction
• Strides Arcolab inks pact with Eli Lilly for cancer drugs
• GSK to spend $904 mn to lift stake in India arm
• Mexico keen on investments from Indian pharmaceuticals companies
• India's Trivitron Healthcare acquires Finnish diagnostics technology firm - Ani Labsystems for
€15.8 Mn (about R110 Cr).
November • India's Cipla offers over Rs.1,200 cr to buy 51 % in Cipla Medpro (S.Africa)
2012 • India's Panacea Biotec announces strategic alliance with Kremers Urban Inc (USA)
• Trivitron Healthcare, India inks pact with Italy-based Diasorin group for Lab devices
• Sun Pharma to acquire US-based DUSA for $230 million
• Mayne Pharma group, Australia inks licensing & distribution agreement with India's Intas Pharma
Source: Press Release, Company websites © Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 20
21. The year 2012 showed some big investment and joint
collaboration taking place in India (2/3)
• Fidelity invests $75 million in India's Trivitron Healthcare
• Pharma industry creates 2nd most # of billionaires
• Australia's Phosphagenics licences injectable technology to Strides Acrolab, India
• Transasia Bio-Medicals Ltd., India’s largest IVD Company Acquires Maxmat S. A., France
• India's Lupin Eyes 15 New Drug Launches in U.S. by March 2013
October • Dr.Reddy's Lab (India) to acquire Netherlands's pharma company- OctoPlus NV for 27.4 million
Euros
2012 • Mylan Inc acquires India's SMS pharmaceuticals units for $33 millions
• Sanofi investing $300 million in India's Shantha Biotechnics facility for Insulin production
• India & China dominates again in BioSpectrum Asia survey
• India's Advinus collaborates with Japan's Takeda in a $90 Million development deal
• India US announce Joint Research in BT
• DBT and ABLE roadmap for a $125B by 2025 Biotech industry from $4B in 2011
• Piramal to launch own innovative drug in EU
• Panacea forms JV with US’ Osmotica
September • India to fund joint medical research project with Cambridge University
2012 • India drug patent on rise- records 3,488 patent in 5 years (2005 - 2010)
• Alembic Pharmaceuticals enters into license agreement with Accu-Break (USA
• Suven Life Sciences secures four products (NCEs) patents
Source: Press Release, Company websites © Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 21
22. The year 2012 showed some big investment and joint
collaboration taking place in India (3/3)
• Australia welcomes research deal with India worth 2.8 million Australian Dollar
August 2012 • Piramal Imaging & IBA Molecular enter pact for diagnostic imaging agent
• Lupin and Novartis in marketing tie-up
• Serum acquires Dutch firm Bithoven for $100M
July 2012 • AstraZeneca & Cellworks to design TB therapies
• Biocon pacts with Bristol Myers for oral insulin development
• Novozymes & Praj to jointly develop Biofuels
• Abbott sets Nutri research center with Biocon
June 2012 • India, Australia collaborate for scientific research
• Advinus Therapeutics Ltd. and P2D Bioscience enter into a R&D collaboration for ADHD
• German Drug Maker Boehringer To Acquire For OTC Brands In India
• Piramal acquires Decision Resources Group, LLC a health-care research provide for $635
May 2012 million
• Merck to set up $150M vaccine lab in Delhi
April 2012 • Piramal acquires Imaging R&D portfolio of Bayer
Source: Press Release, Company websites © Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 22
23. Majority of Indian states host Life Science business centres
in India (1/2)
The Indian Diverse geography caters to many Life Science business centres in India
City Major Companies
Mumbai Sun Pharma, Lupin, Wockhardt, Glenmark, USV, Ipca, Indoco Remedies, Bharat Serum and Vaccines
Ltd, Cipla, FDC, Most MNCs
Ahmedabad Zydus, Cadila, Intas, Torrent, Dishman, Helios, Claris Lifesciences
Hyderabad Dr.Reddy’s, Aurobindo, Suven LifeSciences, Divi’s, Hetero, Shantha Biotech, Granules India, Natco
Pharma, GVK Biosciences
Bengaluru Biocon, Micro, Strides, GSK,Advinus, AstraZeneca, Aurigene, Avesthagen, Bal Pharma, Biozeen,
Bayir Group, Bhat Bio-tech, Camson Bio technologies, Global Calcium, Indigene Life system
New Delhi Ranbaxy, Panacea, Jubilant Life Sciences, Advanced Life Sciences, Akum Drugs & Pharma, Dr. Lal
Path Labs, JagsonPal Pharma, Life Medicare & Biotech, Mankind Pharma, Medicamen Biotech,
ModiMundi Pharma, More pen, Nestor Pharma, Ozone Pharma & Ayurvedic
Chennai Orchid, Shashun, Tablets India, TTK Healthcare, Amrutanjan Health care, Arvind Remedies, Axon
Drugs, Bafna, Caplin Point Labs, Cholayil, Fourrts India Labs, Life Cell International, Malladi Drugs &
Pharma, Medopharm, Nutra Specialities
Pune Bilcare, Serum India, Advinus Emcure, Acoris Research, Hindustan Antibiotics, National Chemical Lab,
Vlife Sciences
Navi Mumbai Reliance Life Science, Pfizer India, Wanbury, Alkem Pharma, Lilac Medicare, Thyrocare Technologies
Source: IndiaBioscience.org © Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 23
24. Majority of Indian states host Life Science business centres
in India (2/2)
The Indian Diverse geography caters to many Life Science business centres in India
City Major Companies
Chandigarh Surya Pharma, Nectar Life Sciences, Ind-Swift Labs
Vishakhapatnam Falcon Biotech, Vijaynagar Biotech Ltd, Actimus Biosciences Pvt.Ltd, Eisai Pharmatechnolgy Ltd,
Techno med systems
Baroda Alembic Pharma, Ambrosia Ltd, Divine Laboratories, Hindustan Biosynth Ltd, Sterling Biotech Unicure
Remedies
Noida & Gurgaon Ranbaxy Labs, Jubilant Life Sciences
Thane Aarti Drugs, Calyx Chemicals & Pharmaceuticals Ltd, Kremoint Pharma, Herbert Brown
Pharmaceuticals & Research
Kolkata Adinath Bio-Labs, Allister Biotech, Krish Biotech, Allen India Ltd, Albert David Ltd, East India
Pharmaceuticals Works, Emami, TCG Lifesciences
Indore Alpa Laboratories, Syncom Healthcare, Biofil Chemicals & Pharmaceuticals Ltd, Cyano Pharma,
Parenteral Drugs India Ltd
Source: IndiaBioscience.org © Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 24
25. India has active Public and Private Institutes focused on
research covering spectrum of Lifesciences (1/2) (Few centers
listed below)
City Centres
New Delhi All India Institute of Medical Sciences, International Centre for Genetic Engineering &
Institute of Genomics and Integrative Biology, (IGIB) Biotechnology (ICGEB)
National Institute of Immunology, Institute of Cytology Jawaharlal Nehru University
and Preventive Oncology (ICPO) TERI University, Nizam's Institute of Medical Sciences
Bengaluru National Centre for Biological Science (NCBS) , National University of Agricultural Sciences, Jawaharlal Nehru
Institute of Mental Health and Neurosciences Centre for Advanced Scientific Research, Indian Institute of
Stem Cell Institute Science (IISc)
Hyderabad Ashoka Trust for Ecology and the Environment LV PRASAD EYE INSTITUTE
International Crops Research Institute for the Semi- National Institute for Nutrition
Arid Tropics (ICRISAT) Indian Institute of Chemical Technology
Centre for Cellular and Molecular Biology (CCMB)
Pune Agarkar Research Institute ,National Institute of Virology (NIV),
Indian Institute of Science Education and Research Microbial Containment Complex
National Chemical Laboratory (NCL) The National Centre for Cell Sciences
National AIDS Research Institute (NARI)
Mumbai Advanced Centre for Treatment Indian Institute of Technology Bombay (IIT- Bombay)
Research and Education in Cancer Tata Institute of Fundamental Research (TIFR)
Bhabha Atomic Research Centre (BARC) University of Mumbai
Bombay Natural History Society
Ahmedabad National Institute of Pharmaceutical Education and The Gujarat Cancer & Research Institute
Research (NIPER) Institute for Plasma Research
National Institute of Occupational Health (NIOH) Indian Institute of Management Ahmedabad (IIM-A)
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 25
26. India has active Public and Private Institutes focused on
research covering spectrum of Lifesciences (1/2) (Few centers
listed below)
City Centres
Kolkata Bose Institute Indian Institute of Science Education and Research
Indian Institute of Chemical Biology Calcutta Medical Research Institute
Indian Statistical Institute Marine Engineering & Research Institute
Jadavpur University Indian Institute of Management (IIM- C)
University of Calcutta
Nagpur Central Institute for Cotton Research National Environmental Engineering Research Institute
National Research Centre for Citrus (NRCC) (NEERI)
Indian Bureau of Mines National Institute of Intellectual Property Management
National Bureau of Soil Survey and Land Use (NIIPM)
Planning
Lucknow Birbal Sahni Institute of Palaeobotany Industrial Toxicology Research Centre (ITRC)
Central Drug Research Institute Indian Institute of Sugarcane Research (IISR)
National Botanical Research Institute
Chennai Indian Institute of Technology Madras The National Institute of Epidemiology (NIE)
University of Madras CENTRAL LEATHER RESEARCH INSTITUTE (CLRI)
National Institute for Research in Tuberculosis
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 26
27. M&A Activity: India as an emerging market is gaining
widespread attention (1/2)
With patent cliff and weak pipeline, there is a continuous pressure on Global companies to explore
avenues including generic business in emerging markets
Recent M&A transactions of Indian Pharma
Indian Co. MNC (acquirer) Nature of Deal
Wockhardt Danone Acquisition for US$ 350 Million (2011)
Paras Pharma Reckitt Benckiser Acquisition for US$ 726 Million (2010)
Piramal Healthcare Abbott Acquisition of domestic Formulation business
for US$ 3.7 billion (2010)
Dabur Fresenius Acquisition of 73. 3% stake for Euro 139
million (2008)
Ranbaxy Daiichi Sankyo Acquisition for US$ 4.6 billion
Shantha Biotechnics Sanofi-Aventis Acquisition for US$ 781 million (2009)
Orchid Hospira Acquisition for US$ 400 million (2009)
Matrix Mylan Acquisition for US$ 736 million (2006)
Source: India Pharma Inc. Enhancing value through Alliances and Partnership – E&Y 2011.
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 27
28. M&A Activity: India as an emerging market is gaining
widespread attention (2/2)
Recent M&A transactions of Indian Pharma
Indian Company MNC (acquirer) Nature of Deal
Vetnex Animal Health Ltd (earlier Pfizer (Animal Health Business) NA (2009)
ICICI Venture acquired from Ranbaxy)
Wockhardt (Animal Care Subsidiary) Vetoquinol SA (France) NA (2009)
Pharma MNCs are facing challenges of impending patents and rising R&D expenditure.
They are looking for opportunities to increase the drug pipeline and reduce costs. In addition, given the
pressures of reducing healthcare costs and the increasing use of generics, pharma MNCs are also looking to
partner with companies with superior product development capabilities.
Source: India Pharma Inc. Enhancing value through Alliances and Partnership – E&Y 2011.; * International journal of Pharmaceutical
Development & Research- Vol-04, May 2012
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 28
29. List of acquisitions by Indian companies in 2011-12 (Indicative)
Zydus has been the most active with involvement in 3 acquisitions
Company Acquisition Market Consideration Rationale
Strengthens Cadila’s presence in
Zydus Cadila Biochem India Not disclosed domestic formulations market
especially in the anti-biotic segment
Not disclosed Expands presence in the animal
Zydus Bremer Pharma Mainly Europe
healthcare business
Allows presence in the controlled-
release drugs segment in the US with
United States product portfolio and
Zydus Cadila Nesher Pharma
(Generics) manufacturing capabilities; step to
strengthen presence in the US
generics market
Allows the company to enter the US
penicillin-containing anti-bacterial
GSK’s Penicillin United States
Dr. Reddy’s $ 20 million market segment with brands
manufacturing facility (Generics)
such as Augmenting and Amoxil and
diversify its generics portfolio in the US
Source: Company Websites, Press Releases
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 29
30. Indian Companies prefer Expansion Pill to expand and
cater wide geographies
Already established in regulated and semi-regulated markets
Indian Co. MNCs Nature of Deal
Mergers & Acquisitions are now
Lupin I’rom Pharmaceuticals (Japan) Undisclosed amount
a days play a key role in Indian
(2011)
Pharma. India stood in top 5
countries in the year 48
Research and development $20 million upfront transactions, total value of 4.9
(R&D) agreement with Medicis payment from Medicis USD millions.
Pharmaceutical (2011)
USA stood in first, next is
Hormosan Pharma GmbH, a Amount not disclosed
Germany and countries like
Generic Company in Germany. (2008)
China, Brazil ranked after India.
Dr.Reddy’s GSK (completion of the Amount not disclosed Indian pharmaceutical
acquisition of US penicillin (2011) companies have spent close to
facility and products from $1.4 bn in acquiring companies
GlaxoSmithKline) globally in the past 18 months.
BASF’s Pharmaceutical Contract Amount not disclosed With access to capital, higher
Manufacturing Business (2008) staying power because of low
Biocon AxiCorp Pharmaceuticals Acquired majority stake costs, and managements willing
of 70% (2008) to globalize, this trend will
continue. (2010)*
Glenmark Medicamenta Amount not disclosed
(2007)
Source: Company Websites, Press Releases
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 30
31. List of JV/Alliances among Indian players(Indicative)
JV/ Alliances Market Rationale
JV would develop, manufacture and market branded generics across emerging
markets;
Sun Pharma’s contribution: Leveraging on SPARC’s R&D pipeline and
Sun Pharma – Merck Emerging Markets
manufacturing capabilities
Merck’s contribution: Market presence and regulatory competence across
emerging markets
Emerging Markets Based on similar structure; DRL would manufacture products; while GSK would
Dr. Reddy’s – GSK
distribute in Latin America, Africa, Middle East and Asia
Cadila Healthcare – Bayer
Primarily a co-marketing arrangement with focus on certain therapy segment
India With product patent regime, Indian players are collaborating with MNCs by in-
licensing patented products in India
Cadila Healthcare would license 24 branded generics to Abbott for 15 emerging
Cadila Healthcare –
Emerging Markets markets; collaboration includes pain management,
Abbott
oncology, CVS, neurological and respiratory diseases
Primarily a co-marketing arrangement with focus on insulin segment
Lupin – Eli Lilly India Aimed at leveraging on Lupin’s marketing & distribution footprint in India and
Eli Lilly’s product portfolio in the insulin segment
Biocon – Bristol Myers Partnership in the research space with focus on discovery & development of
NA
Squibb NCEs. Working on early stage of the development cycle
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 31
Source: Company Websites, Press Releases
32. List of Alliances & Partnership for Product Sourcing
JV/ Alliances MNCs Rationale
Aurobindo Pharma AstraZeneca, Supply of generic medicines for developed
Pfizer and emerging markets (2010)
Strides Arcolab Ltd Pfizer Supply of 67 generic drugs to Pfizer with ffocus on oncology (2008)
Torrent AstraZeneca Supply of 18 products for various market (2010)
Pharmaceuticals
Indoco Remedies Aspen Range of ophthalmic products for 30 emerging markets (2010)
Indoco Remedies Watson Development and manufacture of generic drugs with market size of US$
Pharmaceuticals 670 million (2010)
Cadila Healthcare Altana, Zyban JV structure for the manufacture of patent drugs (2006)
Torrent Novo-Nordisk Contract manufacturing of formulations (2010, 2005)
Pharmaceuticals
Strides GSK Supply of drugs for semi-regulated markets (2011)
Arcolab Limited
Source: Company Websites, Press Releases © Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 32
33. Today, Acquisitions and Partnerships with Indian
companies have expanded to R&D as well
MNCs active in Collaborative Research in India. Previously, they were formed to source out products.
Indian Company Molecule Indication Nature of Deal Global Remark
Partner
Zydus Cadila (2009) Not disclosed Cardiovascular Collaborative Eli Lilly To discover & Develop new CVS drugs for a
research span of 6 yrs
Zydus Cadila (2008) Not disclosed Inflammatory Collaborative Karo Bio To develop a new compound that targets
Diseases research the Gluco corticoid receptor for treatment
of inflammatory disorders
Torrent (2005) Not disclosed Hypertension Collaborative Astra Zeneca To discover a novel drug for hypertension
research for Rs. 1.2 Billion
Suven Life Sciences Pre- clinical CNS Joint Development Eli Lilly Partnering deal for early phase research
(2006) drug for discovery of NCEs
candidate
“Alliances and acquisitions for drug discovery, diagnostics and clinical research is taking place throughout India. Such deals will provide mutual
advantage to both partners. While the MNCs benefit by replenishing pipelines, addition to product portfolios or establishing a local presence in the
emerging markets, the Pharma/ biotech companies gain in technology expertise and much needed funds for research and expansion,”
Dr Ajaykumar Sharma Practice Head - Pharma Healthcare South Asia & Middle East, Frost & Sullivan) Opportunities Galore for India's Biotech
Industry – Express Pharma (1-15 Feb, 2012)
Source: Company Websites, Press Releases © Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 33
34. MNCs outsource their research work to Indian firms owing to it’s rich
domain expertise. Contract research is an established operating model
R & D services agreements by Indian companies
Indian Firm MNC Partner Purpose “As rightly pointed out by Ernst & Young in
Orchid Chemicals Bexel (2006) Drug discovery its ‘Beyond Borders 2005 Report’, for
research in metabolic biotech companies,
disease
>> “Partnerships are an important means of
Biocon BMS (2009) Contract Research for
mitigating risk, as well as a strategic
Pfizer (2010) Bulk drugs
Mylan (2009) Biosimilars response to business challenges..
Jubilant Organosys Eli Lilly NCE : CVS, CNS, >> Since drug development is an inherently
(2005) Diabetics, Oncology, high-risk business, characterised by large
Astra Zeneca (2009) Neuroscience R&D investments and relatively small
probabilities of success, partnerships will
Divis Labs (years data not Merck Custom chemical always be an important factor in diversifying
available, but MNCs name Abbot synthesis and mitigating risk.”
mentioned in public domain) GSK
>> According to Karkaria, partnerships are
also one of the ways of entering newer
Shasun Pharmaceuticals Ltd. Aventis (1998) Contract Research &
Eli Lilly (2001) Custom synthesis potential markets. (Dr Cyrus Karkaria
GSK services President Biotechnology, Lupin)
Teva
Source: Opportunities Galore for India's
Clinigene Pacific Biomarkers (2011) Collaborative research Biotech Industry – Express Pharma (1-15
services agreement to Feb, 2012)
global pharmaceutical
and biotechnology
industry
Source: Battling with TRIPS: Emerging Firm Strategies of Indian Pharmaceuticals Industry Post – TRIPS, Journal of Intellectual Property Rights Vol.
13, July 2008, pp 301- 317 © Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 34
35. Indian Firms Are Looking For Partnerships, Investment,
Licensing or Acquisitions of,
Innovative compounds Co-Development
and technologies Opportunities
Novel Drug Delivery
Systems
Manufacturing in IN and Companies in Regulated
the US markets
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 35
36. About Aagami – Who we Are
Aagami ,Inc. is a life sciences consulting firm based in the suburbs of Chicago, offering Strategic Consulting
and Technology Licensing Services for Life Science (biotech, pharmaceutical and medical devices) companies,
focused on India and Emerging Markets.
Aagami Partners bring several decades of operational experience globally, connections at C-Level people with Indian
Life-sciences companies and most importantly deep knowledge of India-business-practices.
The company has supported small and large life science companies from all over the world, mainly in the United
States, Europe, India, Australia, and Japan in their quest for Indian market and or resources.
These services include finding right service providers, right alliance partners, JV partners, M&A Targets, Contract
Sales/Marketing company, In-Licensing or Out-Licensing deals etc., in the business of Life Sciences including Investing
either way.
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 36
37. Aagami Strategic Consulting offers services in,
In-Licensing or Out-Licensing
Co-Development and Partnerships
Mergers & Acquisitions
Investments to and from India
Finding the Right
• JV partners and/or Distributors
• CRO and CRAMS providers
• Contract Sales/Marketing companies
• Contract Manufacturing companies
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 37
38. Our Value Proposition:
We Bring,
Deep
Extensive network Deal experience Extensive
Dedicated team Understanding of
with top 100 Indian with Western, Operational
with focus on Client business and socio-
LS companies at Japanese and Experience and
success cultural differences
CXO levels Indian industry Excellence Globally
in ways of working
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 38
39. Sample list of Aagami Clients
USA International Clients
Company Location Company Location
Dow MI Solvay Belgium
Aegis CA Delmar Canada
Advangene IL SOM Biotech Spain
MacuCLEAR TX Phosphagenics Australia
DesignMedix OR NanoSensing Brazil
Unitech Pharma MI Affitech Denmark
Loyola U Chicago IL Ilsan Ilvac Turkey
MW Univ. IL, AZ Pieris Germany
PLx TX Toppan Japan
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 39
40. Aagami Approach....
Prepare ‘Elevator Pitch’ on
client technology and/or Identify Relevant
company customized to Broadcast EP to Relevant
Companies from our
Specific business culture Companies by Email
Database and resources
e.g. India, Japan
Coordinate CDAs with
Organize a road show to
interested Companies, and Follow-up with phone calls
India along with client
supply further info through and emails etc.
representative/s
emails and conference calls
Take appointments with Support in structuring and
Coordinate the logistics of
right executives in negotiations for finalizing
the road show
interested companies the deal(s)
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 40
41. Realizing Possibilities
Let’s get in touch… Talk to us or drop by…
Join us in our conversations at,
Global Life Science Dinesh Jain, Founder CEO
Business in India +1 630-853-3520
Dinesh@aagami.net
Our Linkedin group initiative
USA (Head Office) INDIA
2020 Calamos Ct. Suite 209 Crystal Plaza, Level 2, 276 C B Road,
Naperville, IL 60653 Ramdaspeth, Nagpur – 440010
Aagami Home Phone: +1-630-799-1572 Phone: +91-787-501-6957
www.aagami.net
Godwyn Francis Nidhi Bansod
Head –Business Development Head – Business and Market Research
Research Reports, Presentations, godwyn@aagami.net nidhi@aagami.net
Newsletter, and more… Phone:+1- 630-780-5830
Supporting Global companies in Lifesciences to meet success with their India Initiatives…….
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 41
42. SOME MORE INTERESTING FACTS ABOUT INDIA
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 42
43. India home to large number of rich as well as poor classes
Has more Billionaires than Britain, and more poor people than Africa.
India has more number of billionaires than France, UK &
Switzerland. India has a sizeable rich population. India is at the
number four spot on an international list compiled by Forbes
magazine, based on the number of billionaires a country produces.
Poverty has been on the decline. According to official
government of India estimates, poverty declined from 37.2% in
2004-05 to 29.8% in 2009-10. Rural poverty declined by 8
percentage points from 41.8% to 33.8% and urban poverty by
The combined net worth of the 2012 class of the 100 richest 4.8 percentage points from 25.7% to 20.9% over the same
Indian's is $250 billion, up from $241 billion a year ago. India period.
currently has 61 billionaires. (Forbes, October 2012)
The government is now investing in a set of pioneering
In 2008-09, India had 84,000 HNWIs. By 2010, it had risen by 50 initiatives to bring basic services to the poor – in elementary
per cent (126,700), the biggest increase of all countries.* education, basic health care, health insurance, rural roads, and
rural connectivity.
In spite of recent poverty declines with its rapid economic
Source: *Dollar Billionaires in Poor Countries: India’s “Philantrocapitalism”- expansion, India still has high poverty rates according to a
Global Research, Sept 10, 2012; Blog- World Bank on Poverty Across India in 2011 World Bank report titled "Perspectives on poverty in India :
2011-http://www.riazhaq.com/2011/05/world-bank-on-poverty-across-india- stylized facts from survey data" released in 2011. Overall, the
in.html; latest World Bank data shows that India's poverty rate of 27.5%,
Wikipedia- List of countries by the number of US dollar billionaires;
based on India's current poverty line of $1.03 per person per
http://www.worldbank.org/en/country/india/overview
day
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 43
44. India has a well established Education system with
Abundant Talent
India has one of the largest school- age population in the world. It has well established education systems with
more than 1.6 million schools enrolling in excess of 130 mn students
For higher education, India has more than 500 universities as well as more than 25, 000 colleges and 7000
technical institutions with approximately 13 million students.
Education bodies Total numbers
Stream Post graduate Under graduate in India
Science 382619 2000374 Universities 409
Engineering/technology/ 95185 1663691 Number of Arts, Fine arts, social work, 25990
architecture/ design Science &
commerce ;
Medicine 31025 273366 Engineering/technology/architecture;
Management/hotel/travel 125002 181277 Medical ; Education/teacher trainings ;
/tourism Others
management
Education/teacher training 460490 460490 INDIA offers a large, well-educated, English-
Law 11625 203577 speaking workforce with 700,000 scientists
Arts 660516 5108233 and engineers graduating every year,
Commerce 189603 1699263
including 122,000 chemists and chemical
engineers, with 1,500 PhDs#
Ph.D./M.Phill 78388 NA
Note: Figures -Sanctioned intake per million (August 2011)
Source: Report of the Working Group On Science & Technology, Human Resource Development For 12th Five Year Plan (2012-17)- Ministry of Science &
Technology, GOI- Sept 2011. Source: Higher Education Statistics Report 2008-09 by MHRD, (Up to 30 Sept 2008); Report of the Working Group On Science
& Technology, Human Resource Development For 12th Five Year Plan (2012-17)- Ministry of Science & Technology, GOI- Sept 2011; * - India’s
Contribution to the World- http://yousigma.com/interestingfacts/indiasgifttotheworld.pdf, #- Sector Profile Indian Life Sciences – Issue 59- August Page 44
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net
2011http://www.indodutchconnect.com/app/webroot/pdf/newslatter/issue_59/indian_life_sciences.pdf
45. NRIs (PIOs – People of India Origin) constitute a global
community of over 25 million people
Region Population
North America (Mostly USA & Canada) 4.0 Million
South America (Trinidad & Tobago, Guyana, Surinam, Jamaica, etc.) 1.6 Million
Europe (U.K., Netherlands, Germany, Austria, Switzerland, etc.) 2.5 Million
Africa (South Africa, Mauritius, East African countries, etc.) 2.7 Million
Middle East (UAE, Saudi Arabia, Kuwait, etc.) 3.6 Million
Far East & South East Asia (Malaysia, Singapore, Myanmar, etc.) 5.0 Million
Pacific Island (Fiji, Australia, New Zealand) 0.7 Million
Sri Lanka and Nepal 4.9 Million
Total 25.0 Million
Note: Since hard numbers have not been available, these are approximate estimates and obtained from individual country statistics
and from the report of the High Level India Diaspora Committee appointed by Govt. of India
Source: NRIs/PIOs and India – Mutual Expectations
Dr. Thomas Abraham- Chairman, Global Organization of People 2013 | All rights reserved | www.aagami.net
© Aagami, Inc. of Indian Origin (GOPIO), Inc. Page 45
46. This is what Einstein and Duff had to say about India
“We owe a lot to the Indians, who taught us how to count without which no worthwhile scientific
discovery could have been made”
Albert Einstein
“Many of the advances in the sciences that we consider today to have been made in Europe were infact
made in India centuries ago”
Grant Duff - British Historian of India
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 46
47. THANK YOU
END OF DOCUMENT
© Aagami, Inc. 2013 | All rights reserved | www.aagami.net Page 47